Regulation of α-cell glucagon secretion: The role of second messengers

Samuel Acreman1,2 | Quan Zhang1

1 Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK
2 Institute of Neuroscience and Physiology, Department of Physiology, Metabolic Research Unit, University of Gothenburg, Box 430, S-405 30, Gothenburg, Sweden

Correspondence
Quan Zhang, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK, Email: quan.zhang@ocdem.ox.ac.uk

Edited by Yi Cui

Funding information
EFSD European Research Programme on New Targets for Type 2 Diabetes, Grant/Award Number: 96406; Diabetes UK RD Lawrence Fellowship, Grant/Award Number: 14/0005128

1 INTRODUCTION

Diabetes is a metabolic disorder stemming from a loss of proper blood glucose regulation by the islets of Langerhans. Located within the pancreas, these micro-organs are small cell clusters predominantly composed of insulin-secreting β-cells, glucagon-secreting α-cells, and somatostatin-secreting δ-cells. The fact that glucose-lowering insulin secretion and/or signalling is lost in diabetes has led it to be considered as an insulin-related mono-hormonal disease. However, over recent years, this β-cell centric view has been challenged and it has been proposed that diabetes, in fact, has a multi-hormonal aetiology, consisting of dysfunction in the secretion of both insulin and glucagon.

Glucagon is a potent glucose-elevating hormone and normally it is released by α-cells in response to a fall in plasma glucose. It constitutes part of the ‘counter-regulatory’ mechanism of the body by rapidly releasing glucose stored in the liver and stimulating gluconeogenesis, efficiently restoring normal blood glucose levels. The glucose-sensing function of α-cells and the consequent release of glucagon has been demonstrated to become dysregulated in diabetes. As a consequence, hyperglycaemia becomes exacerbated and the risk of severe, life-threatening hypoglycaemia increases dramatically. The importance of the role that glucagon plays in the pathophysiology of diabetes is further supported by studies in which application of glucagon receptor antagonists, thereby blocking glucagon function, was capable of restoring normoglycaemia in β-cell deficient mice. Glucagon is a potent glucose-elevating hormone that is secreted by pancreatic α-cells. While well-controlled glucagon secretion plays an important role in maintaining systemic glucose homeostasis and preventing hypoglycaemia, it is increasingly apparent that defects in the regulation of glucagon secretion contribute to impaired counter-regulation and hyperglycaemia in diabetes. It has therefore been proposed that pharmacological interventions targeting glucagon secretion/signalling can have great potential in improving glycaemic control of patients with diabetes. However, despite decades of research, a consensus on the precise mechanisms of glucose regulation of glucagon secretion is yet to be reached. Second messengers are a group of small intracellular molecules that relay extracellular signals to the intracellular signalling cascade, modulating cellular functions. There is a growing body of evidence that second messengers, such as cAMP and Ca2+, play critical roles in α-cell glucose-sensing and glucagon secretion. In this review, we discuss the impact of second messengers on α-cell electrical activity, intracellular Ca2+ dynamics and cell exocytosis. We highlight the possibility that the interaction between different second messengers may play a key role in the glucose-regulation of glucagon secretion.

KEYWORDS
glucagon, pancreatic islet, second messenger

Abstract
Glucagon is a potent glucose-elevating hormone that is secreted by pancreatic α-cells. While well-controlled glucagon secretion plays an important role in maintaining systemic glucose homeostasis and preventing hypoglycaemia, it is increasingly apparent that defects in the regulation of glucagon secretion contribute to impaired counter-regulation and hyperglycaemia in diabetes. It has therefore been proposed that pharmacological interventions targeting glucagon secretion/signalling can have great potential in improving glycaemic control of patients with diabetes. However, despite decades of research, a consensus on the precise mechanisms of glucose regulation of glucagon secretion is yet to be reached. Second messengers are a group of small intracellular molecules that relay extracellular signals to the intracellular signalling cascade, modulating cellular functions. There is a growing body of evidence that second messengers, such as cAMP and Ca2+, play critical roles in α-cell glucose-sensing and glucagon secretion. In this review, we discuss the impact of second messengers on α-cell electrical activity, intracellular Ca2+ dynamics and cell exocytosis. We highlight the possibility that the interaction between different second messengers may play a key role in the glucose-regulation of glucagon secretion.

KEYWORDS
glucagon, pancreatic islet, second messenger

Abstract
Glucagon is a potent glucose-elevating hormone that is secreted by pancreatic α-cells. While well-controlled glucagon secretion plays an important role in maintaining systemic glucose homeostasis and preventing hypoglycaemia, it is increasingly apparent that defects in the regulation of glucagon secretion contribute to impaired counter-regulation and hyperglycaemia in diabetes. It has therefore been proposed that pharmacological interventions targeting glucagon secretion/signalling can have great potential in improving glycaemic control of patients with diabetes. However, despite decades of research, a consensus on the precise mechanisms of glucose regulation of glucagon secretion is yet to be reached. Second messengers are a group of small intracellular molecules that relay extracellular signals to the intracellular signalling cascade, modulating cellular functions. There is a growing body of evidence that second messengers, such as cAMP and Ca2+, play critical roles in α-cell glucose-sensing and glucagon secretion. In this review, we discuss the impact of second messengers on α-cell electrical activity, intracellular Ca2+ dynamics and cell exocytosis. We highlight the possibility that the interaction between different second messengers may play a key role in the glucose-regulation of glucagon secretion.

KEYWORDS
glucagon, pancreatic islet, second messenger

1 INTRODUCTION

Diabetes is a metabolic disorder stemming from a loss of proper blood glucose regulation by the islets of Langerhans. Located within the pancreas, these micro-organs are small cell clusters predominantly composed of insulin-secreting β-cells, glucagon-secreting α-cells, and somatostatin-secreting δ-cells. The fact that glucose-lowering insulin secretion and/or signalling is lost in diabetes has led it to be considered as an insulin-related mono-hormonal disease. However, over recent years, this β-cell centric view has been challenged and it has been proposed that diabetes, in fact, has a multi-hormonal aetiology, consisting of dysfunction in the secretion of both insulin and glucagon.

Glucagon is a potent glucose-elevating hormone and normally it is released by α-cells in response to a fall in plasma glucose. It constitutes part of the ‘counter-regulatory’ mechanism of the body by rapidly releasing glucose stored in the liver and stimulating gluconeogenesis, efficiently restoring normal blood glucose levels. The glucose-sensing function of α-cells and the consequent release of glucagon has been demonstrated to become dysregulated in diabetes. As a consequence, hyperglycaemia becomes exacerbated and the risk of severe, life-threatening hypoglycaemia increases dramatically. The importance of the role that glucagon plays in the pathophysiology of diabetes is further supported by studies in which application of glucagon receptor antagonists, thereby blocking glucagon function, was capable of restoring normoglycaemia in β-cell
ablated animal models.\textsuperscript{9–12} Whereas efforts have already been made to apply glucagon receptor for the treatment of diabetes,\textsuperscript{3–11} it is undoubtedly clear that therapeutic approaches aiming to restore normal \( \alpha \)-cell function could provide more optimal treatment options for diabetes, given its role in the prevention of hypoglycaemia.

Unlike the well-established \( \beta \)-cell stimulation-secretion coupling model, the precise mechanisms that regulate \( \alpha \)-cell glucagon secretion have yet to reach a consensus. This knowledge gap hampers efforts to fully understand how dysfunction occurs in diabetes. The electrical excitability of \( \alpha \)-cells naturally led to the hypotheses that high glucose inhibits glucagon secretion by modulating \( \alpha \)-cell electrical activity and downstream Ca\(^{2+}\)-dependent exocytosis. To date, proposed mechanisms can be categorised as intrinsic and paracrine: intrinsic mechanisms suggest that glucose metabolism directly modulate activity of \( \alpha \)-cells; while paracrine mechanisms involve factors released from neighbouring \( \beta \)- and \( \delta \)-cells that mediate the inhibitory effects of glucose. These two types of mechanisms are not mutually exclusive and are likely complementary to each other; many of the effects have been proposed to be mediated through second messengers.

Second messengers are a group of small intracellular molecules (e.g., cAMP, Ca\(^{2+}\), IP\(_{3}\)) that amplify/relay extracellular signals (or the ‘first messengers’) to execute biological functions. The effects of glucose on intracellular concentrations of second messengers in \( \beta \)-cells have been well documented,\textsuperscript{16,17} and recent reports indicate metabolic regulation of the same group of molecules also control non-\( \beta \)-cell activity and hormone secretion.\textsuperscript{18–21} In this review, we summarise the current research on glucose regulation of glucagon secretion, with a special focus on the involvement of the ubiquitous second messengers cAMP and Ca\(^{2+}\).

\section{\( \alpha \)-CELL ELECTRICAL ACTIVITY}

Different from \( \beta \)-cells, \( \alpha \)-cells are electrically active and exhibit Ca\(^{2+}\) oscillations at low glucose concentrations (<3 mmol/L). Therefore, for a long time, Ca\(^{2+}\) activity at low glucose was used as the identifying signature of \( \alpha \)-cells in islets.\textsuperscript{22} Interestingly, many of the proteins involved in glucose sensing are similar to that of \( \beta \)-cells, for example, the ATP-sensitive potassium (K\(_{\text{ATP}}\)) channels are identical in both islet cell types.\textsuperscript{23} Considering this, it is rather intriguing that the basal activity of the K\(_{\text{ATP}}\) channels is approximately ten-fold lower than that recorded in \( \beta \)-cells under the same conditions.\textsuperscript{24} As a result, the high input resistance of \( \alpha \)-cells enables the firing of action potentials even when the ambient glucose concentration is low (Figure 1A). The action potentials of \( \alpha \)-cells are often overshooting (>10 mV), suggesting the rapid activating and inactivating voltage-gated Na\(^{+}\) (Na\(_{\text{v}}\)) channels are involved in the upstream of the action potentials. Indeed, Na\(_{\text{v}}\) is expressed in the \( \alpha \)-cells with Na\(_{\text{v}}\) playing an important role in shaping the action potentials.\textsuperscript{25} It is intriguing though that Na\(_{\text{v}}\) current in \( \alpha \)-cells, provides little input to the action potential upstroke – attributable to its negative voltage-dependent inactivation.

Although most electrophysiological evidence showed that \( \alpha \)-cells are electrically active at low glucose, there are conflicting reports regarding their electrical activity when challenged by high glucose (Figure 1B). Using the patch-clamp technique with intact islets, we demonstrated that glucose metabolism induced \( \alpha \)-cell membrane depolarisation and increased firing frequency of action potentials. This coincides with a 20 mV reduction in the action potential amplitude.\textsuperscript{24} We attributed this to reduction in \( \alpha \)-cell K\(_{\text{ATP}}\) channel activity. Once transported into \( \alpha \)-cells, glucose is phosphorylated by high affinity hexokinase 1 (HK1) and low affinity glucokinase (GCK) before being broken down to produce pyruvate, and entering the main ATP-generating citric acid cycle.\textsuperscript{26} ADP is then converted to ATP, increasing the ATP:ADP ratio and closing the K\(_{\text{ATP}}\) channels. The consequent membrane depolarisation partially inactivates Na\(_{\text{v}}\) channels, thereby reducing action potential amplitude.\textsuperscript{24,27–29} While HK1 may control the basal glucose metabolic rate, metabolism of elevated glucose concentrations (>5 mmol/L) is controlled by GCK. Conditional tissue specific ablation of GCK expression in \( \alpha \)-cells resulted in a loss of glucose induced membrane depolarisation and inhibition of glucagon secretion in a mouse model.\textsuperscript{30}

It has also been proposed that high glucose induces membrane depolarisation through the process of glucose entry into the cell. Besides glucose transporters (GLUTs), glucose entry can also be facilitated via the activity of sodium-glucose co-transporters (SGLTs), utilising the Na\(^{+}\) concentration gradient. Both SGLT1 and 2 are expressed in \( \alpha \)-cells, with respective K\(_{\text{m.s}}\) of 2 and 5 mmol/L.\textsuperscript{31–33} These differing affinities between subtypes allows each to play a specific role in the cell. The low K\(_{\text{m}}\) SGLT1 transports glucose at low extracellular concentrations, whereas the high K\(_{\text{m}}\) SGLT2, functions at glucose concentrations that are maximally inhibitory of glucagon secretion. Mathematic modelling suggested the additional Na\(^{+}\) conductance from the activation of SGLT2 contributes to \( \alpha \)-cell membrane depolarisation at high glucose.\textsuperscript{34} However, this cannot be the sole determinant of glucose-induced membrane potential change. If that were the case, glucose-induced depolarisation should occur almost immediately subsequent to elevation of extracellular glucose as it would bypasses glucose metabolism. This differs from experimental evidence demonstrating that membrane depolarisation often develops a few minutes after high glucose was applied.\textsuperscript{24} It is therefore more likely that, rather than delivering a depolarising ion conductance, SGLT2
FIGURE 1 Effect of glucose on α-cell Ca2+ and cAMP at (A) low glucose and (B) high glucose concentrations, which result in changes to glucagon secretion. (A) At low glucose, there is a low rate of glucose transport across the membrane via GLUT and SGLT proteins. Glucose is then converted to glucose-6-phosphate, by hexokinase 1 (HK), to generate ATP via glycolysis. A modest increase in the ATP/ADP ratio, leads to partial closure of KATP-channels, maintaining the membrane potential at the point of allowing action potential (AP) generation: this enables the activation of L-type Ca2+ and Na+ channels. The resulting high-amplitude action potentials activate P/Q-type channels, triggering exocytosis and glucagon release. In addition, adenyl cyclase (AC) production of cAMP primes vesicles for exocytosis and potentiates Ca2+-induced Ca2+ release from the endoplasmic reticulum (ER). Consequently, exocytosis of glucagon-containing vesicles is high. The firing of action potentials can also be attributable to the activation of store-operated Ca2+ entry (SOCE) via ORAI and STIM1, which is triggered by ER Ca2+ depletion due to low SERCA activity.

(B) At high glucose concentrations, there is a high rate of glucose transport into the cytosol, leading to membrane depolarisation. This occurs as a result of increased ATP production via glycolysis, due to substrate abundance: high Km glucokinase (GCK) phosphorylates glucose to produce glucose-6-phosphate. High intracellular ATP results in complete closure of KATP-channels and, consequently, membrane depolarisation. Membrane depolarisation can also be induced by the process of glucose transport through sodium/glucose co-transporters (SGLTs): Na+ is co-transported with glucose and thus provides a depolarising membrane conductance. Na+ channels, at this membrane potential, become inactivated, whereas L-type Ca2+ channels remain activatable and contribute to action potential generation. However, action potential amplitude is reduced at high glucose concentrations (despite firing at a higher frequency) and are no longer able to activate P/Q-type Ca2+ channels, the exocytosis-related Ca2+ channel in α-cells. The effect of membrane depolarisation and higher action potential firing frequency may also lead to increased cytosolic Ca2+ within domains adjacent to Ca2+-sensitive adenylyl cyclase, inhibiting cAMP production and vesicle priming. However, higher ATP may also result in α-cell membrane repolarisation. High ATP-activated SERCA uptake of Ca2+ replenish ER Ca2+, deactivating ORAI-mediated Ca2+ entry, resulting in suppression of α-cell excitability and glucagon secretion. Red arrows indicate action potential propagation. Figure created using BioRender.com

predominantly provides an entry route for glucose (which subsequently goes under metabolism, leading to the closure of KATP channels) parallel to GLUTs.

Differing from our observations, other groups observed α-cell membrane repolarisation in the presence of high glucose concentration.35,36 One of the ion channels suggested to mediate this response is the two-pore domain channel TASK-1.39 TASK-1 channels are small conductance, outwardly rectifying K+ channels active at physiological voltages.57,58 Inhibition of TASK-1 channels increases α-cell electrical activity and, intriguingly, glucose-inhibition of glucagon secretion. Therefore, these channels may function to limit excitability of α-cells at high glucose concentrations.39 However, it remains to be established if/how the TASK-1 channel activity changes in response to glucose metabolism.

In addition to background leak K+ channels, voltage-dependant K+ (Kv) channels are involved in the excitability of α-cells. α-cell Kv channels open at the peak of the action potential, repolarising the membrane and shaping the downstroke of action potentials.39 This hyperpolarising current, activated via Kv2 channels, enables reactivation of voltage-gated Ca2+ (CaV) and Na+, channels, preventing depolarisation-induced inhibition of α-cell action potential firing.40 K+ and Na+ are not the only cations involved in the electrical activity of the α-cell. Ca2+ currents, through CaV channels, also play an important role in the upstroke of the action potential. Blockade of L-type channels, which carry the bulk of the overall Ca2+ current in mice, eliminates action potential generation.41 It is possible that L-type Ca2+ channels function as the pace making channels in α-cells, initiating the action potential firing. The same CaV channel may play a similar role in human α-cell electrical activity.42 However, it is rather counterintuitive that dihydropyridines (e.g., nifedipine or isradipine), potent L-type CaV channel blockers, exert no apparent inhibitory effect on glucagon secretion at low glucose.

2.1 Intracellular Ca2+ store in α-cell electrical activity

Transmembrane Ca2+ currents are not the sole determinants of cellular Ca2+ dynamics and electrical activity. The Ca2+ stored within the endoplasmic reticulum
(ER) has also been proposed to be part of the α-cell metabolic sensing machinery, regulating α-cell electrical activity (Figure 1). It was suggested that the low [ATP]i at low glucose restricts the sarco/endoplasmic Ca2+ ATPase (SERCA) activity, depleting the ER Ca2+ store. This, in turn, activates ER-bound Ca2+ sensing stromal interaction molecules (STIM), which undergo conformational changes, activating Orai1 Ca2+ channel on the plasma membrane. The Ca2+ influx through the Orai1 channels induces membrane depolarisation and α-cell electrical activity.43 This is reversed in response to an increase in extracellular glucose, whereupon higher [ATP]i replenishes ER Ca2+ by the activation of SERCA and subsequently inactivates the store-operated channels (SOCs) to repolarise the membrane.44,45 However, we note here that expression of both Stim and Orai1 is fairly low in the α-cells and direct measurements of Orai1 current is technically challenging. Future studies using newly developed ER Ca2+ probes in conjunction with membrane potential recordings, would provide enlightenment to this intriguing hypothesis.

### 2.2 | Ca2+ in exocytosis

Electrical activity, or action potentials, provide signals for the release of hormones through exocytosis, a process where hormone containing granules fuse with the plasma membrane to release their cargo. As with most neural and exocrine cells, α-cell exocytosis is Ca2+-dependent.46-48 α-cells are equipped with SNARE proteins (a group of proteins that form a complex required for exocytosis): VAMP2; SNAP-25; and Syntaxin-1.49,50 Furthermore, α-cells also express synaptotagmin VII (encoded by Syt7) a SNARE-related Ca2+ sensing protein.51,52 Ablating Syt7 reduced glucose- and depolarisation-triggered cell exocytosis. It is interesting however, that residual exocytosis of Syt7α-cells is sensitive to the N-type Ca2+ channel blocker, ω-conotoxin. This suggests that: (1) α-cells express Ca2+-sensing proteins other than Syt7 and (2) α-cell granules are tightly coupled to a subtype of Ca, (N-type) channel. These, together with observations that N- or P/Q-type Ca2+ channels are the exocytosis-relevant Ca, channels,24,28 despite their relatively low contribution in transmembrane Ca2+ currents, raises the possibility that α-cells exhibit exocytosis ‘hotspots’. It is possible that in these areas N- and/or P/Q-type Ca2+ channels, SNARE complexes, and secretory granules are tightly coupled to form releasing sites for rapid secretion of glucagon through interaction with lipid rafts.53 This is similar to that has been describe in L-type Ca2+ channels and insulin-containing granules in β-cells.54 Interestingly, L-type Ca2+ channels, although conducting >50% of transmembrane Ca2+ currents, play an insignificant role in α-cell exocytosis and glucagon secretion further supporting the existence of specialised release ‘hotspots’ in α-cells.41

As discussed above, increase in intracellular Ca2+ triggers α-cell exocytosis and glucagon secretion. However, interestingly, removal or lowering extracellular Ca2+ below physiological range paradoxically stimulates glucagon secretion.55-57 Perfusion of rat pancreas with solutions containing low Ca2+ (170 µmol/L), transiently stimulated glucagon secretion at both low and high concentrations of glucose, an effect reversed by reintroduction of physiological concentrations of Ca2+ (1.94 mmol/L).46 Furthermore, chelating extracellular Ca2+ by EGTA exerted similar effect on glucagon secretion.55 However, with prolonged exposure to low Ca2+, the initially high secretion of glucagon begins to decline, presumably due to depletion of intracellular Ca2+ stores.46

Mediation of this response to extracellular Ca2+ can be attributed to the Ca2+-sensing receptor (CaSR), a Gαq-coupled GPCR, expressed in both α- and β-cells.58,59 CaSR may also be involved in the glucose-regulation of glucagon secretion and hyperactivity of these receptors (gain-of-function mutations) is correlated to impaired glucose-suppression of glucagon secretion and glucose tolerance.60 However, it is interesting to note that loss-of-function CaSR mutations do not appear to influence glucose tolerance or insulin secretion.42

### 3 | PARACRINE REGULATION OF GLUCAGON

In addition to its intrinsic mechanisms, it has also been proposed that α-cell glucose sensing is, at least in part, mediated by the factors released by neighbouring β- and/or δ-cells, as well as incretins released from the gut.62-65 Because this has been discussed in a number of excellent reviews in the recent years, here we will only briefly review the literature relevant to the topic of this review. We categorise these external regulatory factors as inhibitory or stimulatory (Table 1).

#### 3.1 | Inhibitory factors

Somatostatin (SST), produced by δ-cells, is secreted in response to high glucose and potentiated by both insulin and glucagon.61,78-72 It is a potent inhibitor of both glucagon and insulin, activating Gαi-coupled somatostatin receptor (SSTR) 2 and 5, on α- and β- cells respectively.63,75,76 The effect of SSTRs activation is twofold. On one hand, it inhibits adenyly cyclases, lowering intracellular cAMP, a second messenger that stimulates glucagon secretion.76 On the other hand, it also activates the G-protein-coupled inwardly-rectifying K+ (GIRK) channels.62,73 Opening of the GIRK channels rapidly repolarises α-cells, abolishing α-cells electrical activity and subsequent glucagon secretion.

Beta cells may exert their effects on α-cells through insulin and co-released factors, such as Zn2+ and γ-Aminobutyric acid (GABA). Insulin has long been...
proposed as a negative regulator of glucagon secretion. However, with conflicting effects of insulin on α-cell electrical activity, doubt has been cast on the idea that insulin acts as the primary factor in the suppression of glucagon secretion at high glucose. More recent evidence has demonstrated that the glucagonostatic effect of insulin is exerted by through stimulation of δ-cell SST secretion via SGLTs. Zn²⁺ is packed into insulin-containing granules through Zn²⁺ transporters and is required to stabilise the hexameric insulin crystals within. Consequently, glucose-stimulated insulin secretion will greatly increase intra-islet Zn²⁺ concentration. It has been proposed that Zn²⁺ may activate α-cell K_ATP channels to inhibit α-cell electrical activity. However, its impact on glucagon release from either islets or αTC1-9 cells was unclear. GABA, meanwhile, is an inhibitory neurotransmitter released by β-cells in response to glucose. It activates the A-type GABA receptor (GABA_A), a Cl⁻ channel present on α-cells. This induces membrane hyperpolarization, inhibiting electrical activity and lowering of [Ca²⁺]. Indeed, inhibition of GABA_A increased glucagon secretion at low glucose and reduced the inhibitory effect of glucose on glucagon secretion. It is interesting to note that the GABA_A receptor mediated effect can be enhanced in the presence of high glucose, where intra-islet qinsulin induces higher membrane insertion of the Cl⁻ channel.

Glucagon-like peptide-1 (GLP-1), an incretin produced by intestinal L-cells, was shown to modulate glucagon secretion from α-cells. Although, the low level of GLP-1 receptor expression in α-cells and the observation that GLP-1 inhibited glucagon secretion can be restored by inhibiting SSTR2, led to the hypothesis that GLP-1 effect is mediated by the stimulation of SST secretion. However, we showed that GLP-1 receptors are expressed in α-cells, albeit at low level, and mediate the SST-independent effects of GLP-1 via the activation of PKA.

### 3.2 | Stimulatory factors

Adrenaline’s stimulatory effect on glucagon secretion has been well established. Released in response to various physiological stresses, such as fight-or-flight, exercise, infection and hypoglycaemia. Adrenaline rapidly elevates blood glucose by (1) direct stimulation of hepatic glucose production, (2) stimulation of glucagon and (3) inhibition of insulin secretion. It stimulates α-cells through the activation of α₁ and β-adrenoceptors, which are G_q/11 and G_s coupled receptors, respectively.

While activation of Gα-proteins exerts a strong direct stimulatory effect on α-cell exocytosis via increasing intracellular cAMP concentration, the effect mediated by G_q/11-protein is through PKC, and, potentially, the release of ER Ca²⁺. The G_q/11-protein activates the Phospholipase C (PLC), which cleaves phosphatidylinositol 4, 5 bisphosphate (PIP₂) into 1,4,5-inositol triphosphate (IP₃) and diacylglycerol (DAG). IP₃ subsequently activates the ligand-gated IP₃ receptor, a Ca²⁺-releasing channel located on the ER membrane, increasing cytosolic Ca²⁺ concentration. DAG binds to and activates protein kinase C (PKC), a serine/threonine kinase, on the plasma membrane. This process can be further potentiated by Ca²⁺-induced translocation of PKC to cell membrane. It has been shown that PKC activation by phorbol 12-myristate 12-acetate (PMA) stimulates glucagon secretion, without direct effect on α-cell electrical activity. It is therefore possible that PKC is able to potentiate IP₃R release ER Ca²⁺ and stimulate glucagon release.

Interestingly, glucagon itself can serve as a positive autocrine signal for α-cell glucagon secretion. α-cells are equipped with glucagon receptors (a Gα-coupled receptor) and glucagon was shown to elevate intracellular cAMP concentration, promoting exocytosis. This mechanism can play an important role in glucagon secretion in response to hypoglycaemia, whereupon a large amount of glucagon is required within a short period.
Unlike GLP-1, another incretin produced by gut cells (K or L/K-cells), glucose-dependent insulinotropic polypeptide (GIP) potentiates glucagon secretion. Upon binding to its receptor, GIP stimulates α-cell cAMP production via Gαs-dependent pathway, enhancing glucagon secretion at high glucose levels. It is interesting to note that GIP is also produced by α-cells, albeit relatively low in quantity, possibly contributing to intra-islet paracrine and autocrine regulation.

4 | cAMP

As discussed above, much of the physiological regulation of glucagon secretion is exerted via intracellular changes in α-cell cAMP concentrations. Downstream to the activation of Gαs-coupled receptors, the predominant effect of cAMP is to potentiate glucagon secretion, and this can be replicated with the uncaging of cAMP or application of forskolin. Increases in cAMP concentration stimulate granules docking to the membrane, priming them for exocytosis, and forming the ready releasable pool of granules that can be rapidly released when proximal Ca2+ channels activated, thereby enhancing glucagon secretion. Therefore, it is possible that cAMP represents the key molecule for the glucose sensing in α-cells, as proposed by a recent study. Cyclic AMP is catalysed by adenylyl cyclases (ACs) and hydrolysed by phosphodiesterases (PDEs). Intracellular cAMP concentration can fluctuate rapidly depending on the activities of these two enzymes with opposing actions, resulting in oscillations similar to that seen with Ca2+. Furthermore, the concentration of cAMP is not homogenous throughout the cytoplasm. It is likely to be compartmentalised, constrained by the localised distribution and activities of ACs and PDEs.

4.1 | Production and degradation of cAMP

There are 10 different AC subtypes, with AC3, AC5, AC6, and AC9 expressed in α-cells, AC6 being the most highly expressed. Of these 4 subtypes, AC5 and AC6 have had their presence demonstrated at the protein level by immunohistochemistry. The specific expression of PDEs, meanwhile, is yet to be fully elucidated in α-cells, in contrast to β-cells where their roles have been extensively studied. Transcriptomic studies have revealed the expression of a large number of isoforms in α-cells. Inhibition of PDE3B and PDE4, with cilostamide and rolipram respectively, increases secretion of glucagon at high glucose, while blocking PDE4 also increased glucagon secretion at low glucose. Both PDEs are activated by PKA-dependent phosphorylation and inhibited by cGMP and have been proposed to play a key role in cAMP regulation in α-cells. PDE1C, however, an isozyme expressed at a similar level in both α- and β-cells, may be of particular importance to α-cell function. In β-cells, glucose enhances PDE1C responsiveness through the activity of Ca2+/calmodulin. The higher responsiveness of the isozyme breaks down cAMP faster at high glucose to form a negative feedback pathway for insulin secretion. It can be postulated that the same PDE may play a similar role in the downregulation of glucagon secretion in α-cells, preventing over-secretion of glucagon.

4.2 | Effectors of cAMP

The cellular response to cAMP is mediated by two effectors: the serine/threonine kinase Protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2). PKA binds to four cAMP molecules on the two R subunits of the inactive holoenzyme. This induces a conformational change, releasing the two catalytic subunits, which are then able to phosphorylate PDEs, ACs, glucose transporters, and ion channels.

PKA activation potentiates glucagon secretion at high glucose in murine and human islets, however, this did not occur at low glucose concentrations. It was suggested that PKA is maximally activated at low glucose, but activity at high glucose is curtailed by lower concentrations of cAMP. The main effect can be through the phosphorylation of SNARE proteins, particularly SNAP-25, which primes vesicles for exocytosis. PKA is also able to phosphorylate the IP3R, potentiating Ca2+-induced Ca2+ release from the ER. Finally, PKA is able to self-regulate the levels of cAMP, providing a negative feedback loop, preventing overstimulation. This is performed by phosphorylation of several amino acid sites on ACs, particularly AC5 and AC6, reducing their enzymic activity, converting ATP to cAMP at a lower rate. They also are able to phosphorylate, and consequently activate, PDEs leading to enhanced degradation of cAMP.

The second, and less well studied, of the two major enzymes activated by cAMP binding is EPAC2. Upon binding of cAMP, EPAC2 undergoes a conformational change, freeing the catalytic lobe from the regulatory region. This allows it to act as a guanine-nucleotide-exchange factor (GEF) for a number of targets involved in exocytosis, such as Rap2B, RAP1, RAB3a, and RIM2. EPAC2 is key to cAMP-stimulated glucagon secretion. Mice lacking EPAC2 expression have reduced, though not completely abolished, glucagon secretion in response to adrenaline. This is similar to that seen in β-cells. Unlike PKA, EPAC2 agonists augment glucagon secretion independent of glucose concentration. This is possibly because EPAC2 contains two different cAMP binding domains with different affinities. The effect of EPAC2 on glucagon secretion may be exerted at the level of gene expression and protein production, as well as via
modulation of α-cell exocytosis. For example, SNAP-25 is a target for EPAC2, although these effects may be mediated indirectly via the scaffold-associated protein Rab-interacting molecule 2 (RIM2). RIM2 is key in the interactions within the SNARE complex, interacting with synaptotagmin, RAB3, CaV channels, munc13, and SNAP-25. In β-cells, separation of RIM2 from the exocytotic machinery through deletion of the RAB3 binding domain, impairs exocytosis. RIM2 is highly expressed in α-cells and glucagon secretion in response to insulin increased in Rim2−/− mice.  

Cyclic AMP can therefore function as a molecular switch for α-cell exocytosis, the final step of glucagon secretion. Indeed, capacitance measurements with intracellular application of cAMP demonstrated a steep dependence of α-cell exocytosis to cAMP. Given that α-cell intracellular cAMP concentration is glucose-dependent, it is highly likely to constitute part of the mechanism by which glucose regulates glucagon secretion.

4.3 Effect of cAMP on electrical activity

In addition to their direct effect on the exocytotic machinery, it is possible that cAMP effectors are able to modulate α-cell electrical activity too. Hyperpolarisation-activated cyclic-nucleotide-gated (HCN) channels are members of a superfamily of voltage-gated cation channels that are permeable to both Na+ and K+ ions and produce a slowly activating inward current. The presence of HCN channels has been demonstrated in both primary islet and cells. Unlike most voltage-dependent channels, HCN channels are activated by membrane hyperpolarisation as well as activation of GPCRs that elevate cAMP levels. These greatly facilitate the activation of the channels by shifting their gating voltage by 10 mV or more to more positive potentials. Similarly, NaV channels may be phosphorylated by PKA. This acts to reduce the peak Na+ current through the channel. Furthermore, α-cell Ca2+ conductance is also increased through phosphorylation of N-type or P/Q-type CaV channels, though via EPAC2-dependant mechanisms, and additionally enhanced by RIM2-mediated co-localisation of these with secretory granules.

In addition to the effects on transmembrane Ca2+ influx, α-cell cAMP is able to directly potentiate Ca2+ release from intracellular stores. It was later identified that CAMP-induced ER Ca2+ release is mediated by the PKA/EPAC2-dependent activation of Tpc2 channels located at the lysosomal acidic stores.

5.2 Ca2+ effect on cAMP

When compared with the well-established effect elicited by cAMP on intracellular Ca2+, little is known about how Ca2+ may regulate intracellular cAMP in α-cells. However, all AC isoforms expressed in α-cells can be modulated by factors within Ca2+-signalling pathway, such as PKA, Ca2+/calmodulin-dependent protein kinase (CaMK), or Ca2+/calmodulin-dependent protein kinase (CaMK), or Ca2+ itself. AC3 and AC9 are inhibited indirectly, with CaMKII inhibiting AC3, though only when previously stimulated by Gα. While AC9 is inhibited by phosphorylation by calcineurin. By comparison, AC5 and AC6 are directly inhibited by free Ca2+ through the competitive displacement of free Mg2+ ions key to the catalytic activity of the enzymes. It is therefore possible that Ca2+ plays a regulatory role in the α-cell intracellular cAMP concentration too. As an increase in glucose metabolism is stimulatory to α-cell electrical activity, it is reasonable to postulate that this may lead to an increase in the cytosolic Ca2+ concentration (though the changes may be subtle and restricted within a certain subcellular compartment). This could, in principle, inhibit AC activity and lower the intracellular cAMP concentration, reducing α-cell exocytosis (Figure 1B). This idea was partially tested in a recent study using simultaneous imaging of cAMP and Ca2+. While the authors concluded that Ca2+ had little effect on cAMP oscillations in α-cell, it should be noted the Ca2+ probe used in the study is a strong chelator of Ca2+ and therefore the experimental condition may not have been ideal to address this question. Future studies using less invasive methods may bring novel insights to this interesting interaction of the two second messengers.
In diabetes, α-cell glucose sensing is often impaired, glucagon secretion is no longer stimulated by hypoglycaemia and often cannot be inhibited by hyperglycaemia. Not only does this lead to recurrent hypoglycaemia, a potentially life-threatening medical condition that is currently the limiting factor in glycaemic management of the disease, but also exacerbates hyperglycaemia. Therefore, pharmacological interventions targeting α-cell function will offer safer and better treatment for diabetes. However, despite extensive research on α-cell physiology, the exact mechanism by which glucose regulates glucagon secretion remains obscure. As discussed above, the ubiquitous second messengers, Ca²⁺ and cAMP, are implicated in glucagon secretion, and importantly, can be effectively regulated by glucose metabolism. Therefore, it is highly likely that the synergistic action of these two signalling molecules is at the core of glucose regulation of glucagon secretion. The interaction of intracellular Ca²⁺ and cAMP is complex. Although there is currently no direct experimental evidence, the possible dual role of Ca²⁺ as both a triggering signal and limiting factor (through the inhibition of adenyl cyclases, reducing cAMP) for cell exocytosis could potentially explain the inhibitory action of glucose (and sulfonylurea) on glucagon secretion. With the improvement of cAMP and Ca²⁺ sensors, future studies focusing on their interaction will undoubtedly shed light on α-cell physiology and pathophysiology in diabetes, opening novel avenues for developing better and safer treatment of the disease.

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal Microscopy. J Histochem Cytochem. 2005;53:1087-1097. doi:10.1369/jhc.5C6684.2005
2. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A. 2006;103:2334-2339. doi:10.1073/pnas.0510790103
3. Steiner DJ, Kim A, Miller K, Hara M. Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition. Islets. 2010;2:135-145. doi:10.4161/isl.2.3.11815
4. Weir GC, Bonner Ups 1. 1999;438:428-436. doi:10.1007/s004249900076
5. Shah P, Vella A, Basu A, Basu R, Schwenn WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053-4059. doi:10.1210/jc.2000-014653
6. Greenbaum CJ, Prigneon RL, D’Alessio DA. Impaired β-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes. 2002;51:951-957. doi:10.2337/diabetes.51.4.951
7. Unger RH, Cherrington AD. Glucagononcetric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4-12. doi:10.1172/JCI60016
8. Müller WA, Faloona GR, Unger RH. Hyperglucagonemia in diabetic ketoadacidosis. Its prevalence and significance. Am J Med. 1973;54:52-57. doi:10.1016/0002-9343(73)90083-1
9. Wang M-Y, Yan H, Shi Z, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabeticogenic pathway. Proc Natl Acad Sci. 2015;112:2503-2508. doi:10.1073/pnas.14243112
10. Damond N, Thorel F, Moyer JS, et al. Blockade of glucagon signalling prevents or reverses diabetes onset only if residual β-cells persist. eLife. 2016;5:1-18. doi:10.7554/eLife.13828
11. Wei R, Gu L, Yang J, et al. Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice. iScience. 2019;16:326-339. doi:10.1016/j.isci.2019.05.030
12. Wang MY, Dean ED, Quitiner-Strom E, et al. Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances function of human islets. Proc Natl Acad Sci U S A. 2021;118:1-8. doi:10.1073/pnas.2022142118
13. Schein Al, Paquot N, Lefèvre PJ. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin Investig Drugs. 2017;26:1373-1389. doi:10.1080/13543784.2017.1395020
14. Guan HP, Yang X, Lu K, et al. Glucagon receptor antagonism induces increased cholesterol absorption. J Lipid Res. 2015;56:2183-2195. doi:10.1194/jlr.M060987
15. Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. Diabetes Care. 2016;39:1241-1249. doi:10.2337/dc15-1643
16. Howell SL, Jones PM, Persaud SJ. Regulation of insulin secretion: the role of second messengers. Diabetologia. 1994;37: S30-S35. doi:10.1007/BF00008283
17. Tengholm A. Cyclic AMP dynamics in the pancreatic β-cell. Ups J Med Sci. 2012;117:355-369. doi:10.1039/S0042499032.127432
18. Yu Q, Shuai H, Ahooghalandari P, Gylfe E, Tengholm A. Glucose controls glucagon secretion by directly modulating cAMP in alpha cells. Diabetologia. 2019;62:1212-1224. doi:10.1007/s00125-019-4857-6
19. Tian G, Sandler S, Gylfe E, Tengholm A. Glucose- and hormone-induced cAMP oscillations in α- and β-cells within intact pancreatic islets. Diabetes. 2011;60:1535-1543. doi:10.2337/db10-1087
20. De Marinis YZ, Zhang E, Amisthen S, et al. Enhancement of glucagon secretion in mouse and human pancreatic alpha cells by protein kinase C (PKC) involves intracellular trafficking of PKCalpha and PKCdelta. Diabetologia. 2010;53:717-729. doi:10.1007/s00125-009-1635-x
21. Denwood G, Tarasov A, Salehi A, et al. Glucose stimulates somatostatin secretion in pancreatic δ-cells by cAMP-dependent intracellular Ca²⁺ release. J Gen Physiol. 2019;151:1094-1115. doi:10.1085/jgp.201912351
22. Rorsman P, Hellman B. Voltage-activated currents in guinea pig pancreatic α2 cells: Evidence for Ca²⁺–dependent action potentials. J Gen Physiol. 1988;91:223-242. doi:10.1085/jgp.91.2.223
23. Bokvist K, Olsen HL, Hoy M, et al. Characterisation of sulphonylurea and ATP-regulated K⁺ channels in rat pancreatic α-cells. Pflugers Arch. 1999;438:428-436. doi:10.1007/s004249900076
24. Zhang Q, Ramacheya R, Lahmann C, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18:871-882. doi:10.1016/j.cmet.2013.10.014
25. Zhang Q, Chibalina MV, Bengtsson M, et al. Na⁺ current properties in islet α- and β-cells reflect cell-specific Scn3a and Scn9a expression. J Physiol. 2014;592:4677-4696. doi:10.1113/jphysiol.2014.274299
26. Heimberg H, De Vos A, Moens K, et al. The glucose sensor protein glucokinase is expressed in glucagon-producing α-cells. Proc Natl Acad Sci U S A. 1996;93:7036-7041. doi:10.1073/pnas.93.14.7036
27. Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM. Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature. 1997;387:179-183. doi:10.1038/371940

28. MacDonald PE, De Marinis YZ, Ramracheya R, et al. A KATP channel-dependent pathway within α-cells regulates glucagon release from both rodent and human islets of langerhans. PLoS Biol. 2007;5:1236-1247. doi:10.1371/journal.pbio.0050143

29. Gopel SO, Kanno T, Barg S, Rorsman P. Patch-clamp characterisation of somatostatin-secerting δ-cells in intact mouse pancreatic islets. J Physiol. 2000;528:497-507. doi:10.1111/j.1469-7793.2000.00497.x

30. Basco D, Zhang Q, Salehi A, et al. A-Cell Glucokinase Suppresses Glucose-Regulated Glucagon Secretion. Nat Commun. 2018;9:9. doi:10.1038/s41467-018-03034-0

31. Hummel CS, Lu C, Loo DDF, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose co-transporters SGLT1 and SGLT2. Am J Physiol - Cell Physiol. 2011;300:C14-21. doi:10.1152/ajpcell.00388.2010

32. Bonner C, Kerr-Conje J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517. doi:10.1038/nm.3928

33. Sugita T, Kikuchi O, Kobayashi M, et al. SGLT1 in pancreatic α-cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1-12. doi:10.1016/j.molmet.2018.10.009

34. Pedersen MG, Ahlstedt I, El Hachmane MF, Gopel SO. Dapagliflozin stimulates glucagon secretion at high glucose: Experiments and mathematical simulations of human α-cells. Sci Rep. 2016;6:1-9. doi:10.1038/srep31214

35. Manning Fox JE, Gylkhandyan AV, Satin LS, Wheeler MB. Oscillatory membrane potential response to glucose in islet α-cells. Mol Endocrinol. 2015;29:777-787. doi:10.1210/me.2014-1321

36. Gromada J, Ma X, Hay M, et al. ATP-sensitive K+ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1/- mouse α-cells. Diabetes. 2004;53:181-189. doi:10.23736/s0012-5842.04-5181x

37. Dadi PK, Luo B, Vierra NC, Jacobson DA. TASK-1 potassium channels limit pancreatic α-cell calcium influx and glucagon secretion. Mol Endocrinol. 2015;29:777-787. doi:10.1210/me.2014-1321

38. Gromada J, Bokvist K, Ding WG, et al. Adrenaline stimulates glucagon secretion in pancreatic A-cells by increasing the Ca2+ current and the number of granules close to the L-type Ca2+ channels. J Gen Physiol. 1997;110:217-228. doi:10.1085/jgp.110.3.3217

39. Ramracheya R, Ward C, Shigeto M, et al. Membrane potential-dependent inactivation of voltage-gated ion channels in α-cells inhibits glucagon secretion from human islets. Diabetes. 2010;59:2198-2208. doi:10.23736/db09-1505

40. Derler I, Jardin I, Romain C. Molecular mechanisms of STIM/Orai communication. Am J Physiol - Cell Physiol. 2016;310:C643-C662. doi:10.1152/ajpcell.00007.2016

41. Liu YJ, Vieira E, Gyly E. A store-operated mechanism determines the activity of the electrically excitable glucagon-secreting pancreatic α-cell. Cell Calcium. 2004;35:357-365. doi:10.1016/j.cca.2003.10.002

42. Vieira E, Salehi A, Gyly E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia. 2007;50:370-379. doi:10.1007/s00125-006-0511-1

43. Leclercq-Meyer V, Rebello O, Marchand J, Malaisse W. Glucagon release: paradoxical stimulation by glucose during calcium deprivation. Science (80-). 1975;189:897-899. doi:10.1126/science.1098149

44. Gerich JE, Frankel BJ, Fainska R, West L, Forsmann PH, Grodsky GM. Calcium dependency of glucagon secretion from the in vitro perfused rat pancreas. Endocrinology. 1974;94:1381-1385. doi:10.1210/en-94-5-1381

45. Barg S, Galvanovskis J, Gopel SO, Rorsman P, Eliasson L. Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting α-cells. Diabetes. 2000;49:1500-1510. doi:10.2337/diabetes.49.9.1500

46. DiGruccio MR, Mawla AM, Donaldson CJ, et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that gshulin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol Metab. 2016;5:449-458. doi:10.1016/j.molmet.2016.04.007

47. Andersson SA, Pedersen MG, Vikman J, Eliasson L. Glucose-dependent docking and SNARE protein-mediated exocytosis in mouse pancreatic alpha-cell. Pflugers Arch Eur J Physiol. 2011;462:443-454. doi:10.1007/s00424-011-0979-5

48. Gustavsson N, Wei SH, Hoang DN, et al. Synaptotagmin-7 is a principal Ca2+ sensor for Ca2+-induced glucagon exocytosis in pancreas. J Physiol. 2009;587:1169-1178. doi:10.1113/jphysiol.2008.168005

49. Leung YM, Kwan EP, Ng B, Kang Y, Gaisano HY. SNAREing voltage-gated K+ and ATP-sensitive K+ channels: Tuning β-cell excitability with saxitoxin-1A and other exocytotic proteins. Endocr Rev. 2007;28:653-663. doi:10.1210/er.2007-00110

50. Xia F, Leung YM, Gaisano G, et al. Targeting of voltage-gated K+ and Ca2+ channels and soluble N-ethylmaleimide-sensitive factor attachment protein receptors to cholesterol-rich lipid rafts in pancreatic α-cells: Effects on glucagon stimulus-secretion coupling. Endocrinology. 2007;148:2157-2167. doi:10.1210/en.2006-1296

51. Barg S, Ma X, Eliasson L, et al. Fast exocytosis with few Ca2+ channels in insulin-secreting mouse pancreatic B cells. Biophys J. 2001;81:3308-3323. doi:10.1016/S0006-3495(01)75964-4

52. Leclercq-Meyer V, Marchand J, Malaisse W. The effect of calcium and magnesium on glucagon secretion. Endocrinology. 1973;93:1360-1370. doi:10.1210/endo-93-6-1360

53. Lundquist I, Fornska R, Grodsky GM. Direct calcium-stimulated release of glucagon from the isolated perfused rat pancreas and the effect of chemical sympathectomy. Endocrinology. 1976;98:815-818. doi:10.1210/endo-98-3-815

54. Lundquist I, Forna R, Grodsky GM. Interaction of calcium and glucose on glucagon secretion. Endocrinology. 1976;99:1304-1312. doi:10.1210/endo-99-5-1304

55. Squires PE, Harris TE, Persaud SJ, Curtis SB, Buchan AMJ, Jones PM. The extracellular CaSR on human β-cells: A comparison of islet α-cell electrical activity in mouse and rat. Endocrinology. 2006;147:4655-4663. doi:10.1210/endo-98-3-815

56. Regard JB, Sato IT, Coughlin SR. Anatomical Pro...
Vergari E, Knudsen JG, Ramracheya R, et al. Insulin inhibits glucagon secretion from mouse pancreatic α-cells. *Diabetes*. 2005;54:1789-1797. doi:10.2337/diabetes.54.6.1789

Yoshimoto Y, Fukuyama Y, Horio Y, Inanobe A, Gotoh M, Kurachi Y. Somatostatin induces hyperpolarization in pancreatic islet β-cells by activating a G protein-gated K⁺ channel. *FEBS Lett.* 1999;444:265-269. doi:10.1016/S0014-5793(99)00776-9

Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. *Endocrinology*. 2000;141:111-117. doi:10.1210/endo.141.1.7263

Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic α-cells. *Diabetes*. 2005;54:1789-1797. doi:10.2337/diabetes.54.6.1789

Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Inhibition of pancreatic α-cells by glucose depends on aminobutyric acid (GABA) as an autocrine excitatory transmitter in human pancreatic β-cells. *Diabetes*. 2010;59:1694-1701. doi:10.2337/db09-0797

Xu E, Kumar M, Zhang Y, et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. *Cell Metab*. 2006;3:347-58. doi:10.1016/j.cmet.2005.11.015

Orgaard A, Holst J. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. *Diabetologia*. 2017;60:1731-1739. doi:10.1007/s00125-017-4315-2

Ding WG, Renström E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucose-dependent insulinoctropic polyptide stimulate Ca2⁺-induced secretion in rat α-cells by a protein kinase A-mediated mechanism. *Diabetes*. 1997;46:792-800. doi:10.2337/diabetes.46.5.792

Ramracheya R, Chapman C, Chibalina M, et al. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca 2+ channels. *Physiol Rep*. 2018;6:1-17. doi:10.14814/phy2.13852

de Martinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2⁺ channel-dependent exocytosis. *Cell Metab*. 2010;11:543-553. doi:10.1016/j.cmet.2010.04.007

Verberne AJM, Korim WS, Sabebhagam A, Llewellyn-Smith JH. Adrenaline: Insights into its metabolic roles in hypoglycaemia and diabetes. *Br J Pharmacol*. 2016;173:1425-1437. doi:10.1111/bph.13458

Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. *Diabetologia*. 2000;43:533-549. doi:10.1007/s001250051341

Hirose H, Maruyama H, Ito K, Kido K, Koyama K, Saruta T. Effects of α₂- and β-adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin-induced diabetic rats. *Metabolism*. 1993;42:1072-1076. doi:10.1016/0026-0495(93)90025-J

Vieira E, Liu YJ, Glyffe E. Involvement of α₁ and β-adrenoceptors in adrenaline stimulation of the glucagon-secreting mouse α-cell. *Naunyn Schmiedebergs Arch Pharmacol*. 2004;369:179-183. doi:10.1007/s00210-003-0858-5

Hamilton A, Zhang Q, Salehi A, et al. Adrenaline stimulates glucagon secretion by Tpc2-Dependent Ca2⁺ mobilization from acidic stores in pancreatic α-cells. *Diabetes*. 2016;67:1128-1139. doi:10.2337/db17-1102

Berridge MJ. Inositol trisphosphate and calcium signalling mechanisms. *Biochim Biophys Acta - Mol Cell Res*. 2009;1793:933-940. doi:10.1016/j.bbrc.2008.10.005

Huang KP. The mechanism of protein kinase C activation. *Trends Neurosci*. 1989;12:425-432. doi:10.1016/0166-2236(89)90091-X

Hii CST, Stutchfield J, Howell SL. Enhancement of glucagon secretion from isolated rat islets of Langerhans by phorbol 12-myristate 13-acetate. *Biochem J*. 1986;233:287-289. doi:10.1042/bj2330287

Ma X, Zhang Y, Gromada J, et al. Glucagon stimulates exocytosis in mouse and rat pancreatic α-cells by binding to glucagon receptors. *Mol Endocrinol*. 2005;19:198-212. doi:10.1210/me.2004-0059

De Heer J, Rasmussen C, Coy DH, Holst J.J. Glucagon-like peptide-1, but not glucose-dependent insulinoctropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. *Diabetologia*. 2008;51:2263-2270. doi:10.1007/s00125-008-1149-y

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology*. 2007;133:2131-2157. doi:10.1053/j.gastro.2007.03.054

Gremlich S, Porret A, Hani EH, et al. Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinoctropic Polypeptide
114. Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. *J Biol Chem*. 2004;279:45471-45481. doi:10.1074/jbc.M40763200

115. Dyachok O, Gylfe E. Ca2+‐induced Ca2+ release via inositol 1,4,5-trisphosphate receptors is amplified by protein kinase A and triggers exocytosis in pancreatic β‐cells. *J Biol Chem*. 2004;279:8057-8081. doi:10.1074/jbc.T100068200

116. Britsch S, Krippeit D, Lang F, Gregor M, Drewes G. Glucagon‐like peptide‐1 modulates Ca2+ current but not K+ATP current in intact mouse pancreatic B‐cells. *Biochem Biophys Res Commun*. 1995;207:33-39. doi:10.1016/0006-291X(94)01277-I

117. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/ Rap1 signaling in regulation of insulin granule dynamics by cAMP. *Proc Natl Acad Sci U S A*. 2007;104:19333-19338. doi:10.1073/pnas.0707054104

118. Park JH, Kim SJ, Park SH, et al. Glucagon‐like peptide‐1 enhances glucokinase activity in pancreatic β‐cells through the association of Epac2 with Rim2 and Rab5A. *Endocrinology*. 2012;153:574-582. doi:10.1210/en.2011-0259

119. Kashima Y, Miki T, Shibasaki T, et al. Critical Role of cAMP‐GEFII‐Rim2 Complex in Incretin‐potentiated Insulin Secretion. *J Biol Chem*. 2001;276:46046-46053. doi:10.1074/jbc.M103782000

120. De Rooij J, Rehmann H, Van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP‐dependent RapGEFs. *J Biol Chem*. 2000;275:20829-20836. doi:10.1074/jbc.M00113200

121. Islam D, Zhang N, Wang P, et al. Epac is involved in cAMP‐stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic α‐ And intestinal L‐cell lines. *Am J Physiol - Endocrinol Metab*. 2009;296:174-181. doi:10.1152/ajpendo.90419.2008

122. Vikman J, Svensson H, Huang YC, et al. Truncation of SNAP‐25 reduces the stimulatory action of cAMP on rapid exocytosis in insulin‐secreting cells. *Am J Physiol - Endocrinol Metab*. 2009;297:452-461. doi:10.1152/ajpendo.90585.2008

123. Ozaki N, Shibasaki T, Kashima Y, et al. cAMP‐GEFII is a direct target of cAMP in regulated exocytosis. *Nat Cell Biol*. 2002;4:805-811. doi:10.1038/35041046

124. Coppola T, Magnin‐Lüthi S, Perret‐Menoud V, Gattesco S, Schiavo G, Regazzi R. Direct Interaction of the Rab3 E GEFII·Rim2 Complex in Incretin Cell Glucagon Secretion. *Diabetes*. 2010;59:1170-1178. doi:10.2337/db13-1607

125. Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S. Interaction of ATP Sensor, cAMP Sensor, Ca2+ Sensor, and Voltage‐dependent Ca2+ Channel in Insulin Granule Exocytosis. *J Biol Chem*. 2004;279:7956-7961. doi:10.1074/jbc.M309068200

126. Yasuda T, Shibasaki T, Minami K, et al. Rim2a determines docking and priming states in insulin granule exocytosis. *Cell Metab*. 2010;12:117-129. doi:10.1016/j.cmet.2010.05.017

127. Zhang Y, Zhang N, Gyuilkhandanyan AV, et al. Presence of functional hyperpolarisation‐activated cyclic nucleotide‐gated channels in clonal alpha cell lines and rat islet alpha cells. *Diabetologia*. 2005;48:2299-2308. doi:10.1007/s00125-005-1166-x

128. Robinson RB, Siegelbaum SA. Hyperpolarization‐Activated Cation Currents: From Molecules to Physiological Function. *Ann Rev Physiol*. 2003;65:453-480. doi:10.1146/annurev.physiol.65.092101.142734

129. Li M, West JW, Lai Y, Scheuer T, Catterall WA. Functional modulation of brain sodium channels by cAMP‐dependent phosphorylation. *Neuron*. 1992;8:1151-1159. doi:10.1016/0896-6771(92)90135-Z

130. Cantrell AR, Scheuer T, Catterall WA. Voltage‐dependent neuromodulation of Na+ channels by D1‐like dopamine receptors in rat hippocampal neurons. *J Neurosci*. 1999;19:5301-5310. doi:10.1523/jneurosci.19-13-05301.1999

131. Schiffmann SN, Lledo PM, Vincent JD. Dopamine D1 receptor modulates the voltage‐gated sodium current in rat striatal neurons through a protein kinase A. *J Physiol*. 1995;483:95-107. doi:10.1113/jphysiol.1995.sp020570

132. Bünemann M, Gerhardstein BL, Gao T, Hosey MM. Functional regulation of L‐type calcium channels via protein kinase A‐mediated phosphorylation of the J2 subunit. *J Biol Chem*. 1999;274:33851-33854. doi:10.1074/jbc.274.48.33851

133. Ämmälä C, Ashcroft FM, Rorsman P. Calcium‐independent potentiation of insulin release by cyclic AMP in single β‐cells. *Nature*. 1993;363:356-358. doi:10.1038/36356a0

134. Kæser PS, Deng L, Wang Y, et al. RIM proteins tether Ca2+ channels to presynaptic active zones via a direct PDZ‐domain
interaction. Cell. 2011;144:282-295. doi:10.1016/j.cell.2010.12.029

135. Johansson H, Gylfe E, Hellman B. Cyclic AMP raises cytoplasmic calcium in pancreatic α2-cells by mobilizing calcium incorporated in response to glucose. Cell Calcium. 1989;10:205-211. doi:10.1016/0143-4160(89)90003-1

136. Wayman GA, Impey S, Storm DR. Ca2+ inhibition of type III adenylyl cyclase in vivo. J Biol Chem. 1995;270:21480-21486. doi:10.1074/jbc.270.37.21480

137. Wang H, Storm DR. Calmodulin-Regulated Adenylyl Cyclases: Cross-Talk and Plasticity in the Central Nervous System. Mol Pharmacol. 2003;63:67-92. doi:10.1124/mol.63.3.463

138. Antoni FA, Palkovits M, Simpson J, et al. Ca2+/calcineurin-inhibited adenylyl cyclase, highly abundant in forebrain regions, is important for learning and memory. J Neurosci. 1998;18:9650-9661. doi:10.1523/jneurosci.18-23-09650.1998

139. Cech SY, Broaddus WC, Maguire ME. Adenylate cyclase: The role of magnesium and other divalent cations. Mol Cell Biochem. 1980;33:67-92. doi:10.1007/BF00224572

140. Guillou JL, Nakata H, Cooper DMF. Inhibition by calcium of mammalian adenylyl cyclases. J Biol Chem. 1999;274:35539-35545. doi:10.1074/jbc.274.50.35539

141. Shah P, Basu A, Basu RR, Rizza RA. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol - Endocrinol Metab. 1999;277:283-290. doi:10.1152/ajpendo.1999.277.2.e283

142. Gilon P. The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes. J Mol Biol. 2020;432;1367-1394. doi:10.1016/j.jmb.2020.01.004

143. Stanojevic V, Habener JF. Evolving function and potential of pancreatic alpha cells. Best Pract Res Clin Endocrinol Metab. 2015;29:859-871. doi:10.1016/j.beem.2015.10.002

144. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45:937-948. doi:10.1007/s00125-002-0822-9

145. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia. 1995;38:337-343. doi:10.1007/BF00400639

How to cite this article: Acreman S, Zhang Q. Regulation of α-cell Glucagon Secretion: The Role of Second Messengers. Chronic Dis Transl Med. 2022;8:7-18. doi:10.1016/j.cdtm.2021.06.001